HEALTH & SCIENCE — A major breakthrough by Moderna and Merck could open the door to a new generation of personalized cancer vaccines after their experimental mRNA treatment showed promising late-stage results in patients with high-risk melanoma.

The treatment, known as intismeran autogene, is designed specifically for each patient's tumor. Used alongside Merck's immunotherapy Keytruda, it is intended to train the immune system to recognize and attack cancer cells carrying mutations unique to the patient's tumor.

The latest results have raised hopes that the same technology could eventually be adapted to treat other types of cancer.

A Different Approach to Fighting Cancer

Traditional cancer treatments often attack rapidly dividing cells, which can include both cancerous and healthy tissue.

Immunotherapy takes a different approach by helping the body's immune system recognize and attack cancer.

Personalized cancer vaccines go a step further. Scientists analyze a patient's tumor to identify mutations that distinguish the cancer cells from healthy cells. They then use that information to create an individualized vaccine designed to teach the immune system what to look for.

This means the vaccine is not necessarily the same for every patient. Instead, it is designed around the biological characteristics of an individual's tumor.

The Moderna-Merck Vaccine

Moderna and Merck's candidate, intismeran autogene, uses messenger RNA technology to deliver instructions that help the immune system recognize tumor-specific targets.

The vaccine is being tested in combination with Keytruda, an established immunotherapy drug that blocks the PD-1 pathway and helps immune cells remain active against cancer.

The companies' earlier five-year follow-up data from a Phase 2b study showed a 49% reduction in the risk of recurrence or death compared with Keytruda alone among patients with high-risk stage III or IV melanoma following complete tumor removal. The same analysis showed a 59% reduction in the risk of distant metastasis or death.

The Latest Trial Is Bigger

The latest breakthrough comes from a large Phase 3 trial involving more than 1,000 people with high-risk melanoma.

Patients had undergone surgery to remove their tumors and were then treated with either Keytruda alone or the combination of Keytruda and the personalized mRNA vaccine.

The companies reported that the combination significantly reduced the risk of melanoma returning or spreading compared with Keytruda alone.

However, the companies have not yet released the complete detailed results publicly, meaning researchers will need to examine the full data before the significance of the findings can be independently assessed.

Why Melanoma Is an Important Test

Melanoma is particularly interesting for personalized cancer vaccines because these tumors can contain many genetic mutations.

Those mutations can create recognizable targets for the immune system.

If a vaccine can successfully teach immune cells to identify those targets, it could potentially help destroy microscopic cancer cells left behind after surgery before they develop into new tumors.

That is particularly important because surgery may remove the visible tumor while microscopic cancer cells can remain elsewhere in the body.

This Is Not Yet a Universal Cancer Vaccine

The breakthrough should not be misunderstood.

Moderna and Merck have not produced a single vaccine capable of preventing or curing every type of cancer.

The current treatment is a personalized therapeutic vaccine designed for people who already have cancer or have had a cancerous tumor removed.

It is therefore fundamentally different from vaccines used to prevent infectious diseases such as measles or influenza.

Why the Results Could Be Bigger Than Melanoma

The real significance of the development is whether the technology can work across multiple cancers.

Moderna and Merck are already studying the approach in other tumor types, including non-small cell lung cancer, bladder cancer and kidney cancer.

Additional research is also exploring its potential in pancreatic and stomach cancers.

The companies currently have multiple Phase 2 and Phase 3 studies investigating the technology across different cancer types.

Why mRNA Could Change Cancer Treatment

One major advantage of mRNA technology is flexibility.

Instead of manufacturing a completely different conventional drug for every possible tumor mutation, researchers can use the mRNA platform to encode information targeting the mutations identified in an individual patient's cancer.

That creates the possibility of producing highly personalized treatments using a technology that can potentially be adapted to different cancers.

The success of mRNA vaccines during the COVID-19 pandemic also demonstrated that the technology can be developed and manufactured at large scale, although personalized cancer vaccines present a much more complicated manufacturing challenge.

The Manufacturing Challenge

Personalization is also one of the biggest obstacles.

A conventional medicine can be manufactured in large batches and distributed to thousands or millions of patients.

A personalized cancer vaccine requires information from an individual patient's tumor before the treatment can be designed.

That creates a complicated process involving tumor sequencing, identifying appropriate mutations, designing the vaccine and manufacturing an individualized dose.

The speed, cost and reliability of that process will be crucial if personalized cancer vaccines are ever to become widely available.

Doctors Are Hopeful, but Caution Remains Necessary

The latest results are significant, but experts are not yet declaring victory over cancer.

Melanoma may be particularly suitable for this strategy because of its relatively high number of mutations.

A treatment that works well in melanoma may not automatically produce the same results in cancers with fewer useful mutations or different biological characteristics.

Full clinical data will therefore be important in determining how broadly the technology can be applied.

The FDA Has Already Recognized the Potential

The personalized vaccine received Breakthrough Therapy designation from the US Food and Drug Administration in 2023 for use with Keytruda in high-risk melanoma following complete tumor removal.

The designation was based on earlier positive results from the Phase 2b KEYNOTE-942 study.

It does not mean the treatment has been approved, but it reflects the FDA's assessment that the therapy may offer a meaningful improvement over existing treatment options for the targeted patient population.

A New Race in Cancer Vaccines

Moderna and Merck are not alone.

Other pharmaceutical companies and biotechnology firms are also pursuing personalized mRNA and neoantigen cancer vaccines.

Companies including BioNTech and Roche are developing competing approaches, increasing the possibility that the field could develop rapidly if late-stage trials continue to produce positive results.

The Moderna-Merck results could therefore serve as an important validation of the broader strategy rather than simply being a breakthrough for two companies.

What Happens Next?

The next major step will be the release and presentation of detailed Phase 3 results.

Regulators will then need to assess the complete evidence on effectiveness, safety and manufacturing before deciding whether the treatment can be approved.

The companies are expected to engage with regulatory authorities as they move toward potential applications.

If the results withstand detailed scientific and regulatory review, the treatment could eventually become one of the first personalized mRNA cancer therapies to reach routine clinical use.

Our Perspective

The most important part of this development is not the phrase "cancer vaccine." It is the underlying idea that cancer treatment could become increasingly personalized.

Instead of treating every patient with the same cancer using essentially the same approach, doctors could increasingly use the genetic profile of an individual's tumor to design treatment specifically for that person.

That is a much more ambitious transformation than simply creating another cancer drug.

But the evidence must be allowed to speak for itself. The results are highly promising, yet the complete Phase 3 data and regulatory review are still necessary before this becomes a proven, widely available treatment.

Conclusion

Moderna and Merck's latest results represent an important milestone for personalized cancer treatment. Their experimental mRNA vaccine, used with Keytruda, has shown that a treatment designed around mutations unique to a patient's tumor can reduce the risk of melanoma recurrence and spread.

The breakthrough is particularly significant because the companies are testing the same underlying technology against several other cancers.

There is still a long road from promising trial results to widespread clinical use. Manufacturing personalized vaccines, proving their effectiveness across different cancers and securing regulatory approval remain major challenges.

Nevertheless, if the approach continues to succeed, cancer vaccines could move from an experimental concept into a new class of personalized treatments — potentially changing how doctors fight cancer after surgery and how the immune system is used against tumors.

Daily Touch Insights Editorial Team
View Journalist Profile